Use of cannabinoids in the treatment of epilepsy
View Patent ↗The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
1. A method of reducing seizure frequency in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof clobazam and cannabidiol (CBD), wherein the purity of the CBD is at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day.
2. The method of claim 1 , wherein the administering reduces total convulsive seizure frequency.
3. The method of claim 1 , wherein the patient was administered clobazam prior to administering the combination of the CBD and the clobazam.
4. The method of claim 1 , wherein the CBD comprises 49-tetrahydrocannabinol (THC) impurity.
5. The method of claim 1 , wherein the CBD is administered at a dose of 5 mg/kg/day and increased by 2 to 5 mg/kg increments to at least 10 mg/kg/day.
6. The method of claim 1 , wherein the dose of the CBD is 10 mg/kg/day.
7. The method of claim 1 , wherein the dose of the CBD is 12 mg/kg/day.
8. The method of claim 1 , wherein the dose of the CBD is 14 mg/kg/day.
9. The method of claim 1 , wherein the dose of the CBD is 15 mg/kg/day.
10. The method of claim 1 , wherein the dose of the CBD is 18 mg/kg/day.
11. The method of claim 1 , wherein the dose of the CBD is 20 mg/kg/day.
12. A method of treating seizures in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof clobazam and cannabidiol (CBD), wherein the purity of the CBD is at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD is at least 10 mg/kg/day.